Sawant Rishikesh M, Cohen Michael B, Torchilin Vladimir P, Rokhlin Oskar W
Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.
J Drug Target. 2008 Aug;16(7):601-4. doi: 10.1080/10611860802228954.
Long-circulating liposomes loaded with doxorubicin (Dox) were additionally modified with the prostate cell-specific monoclonal antibody 5D4 (mAb 5D4). The resultant Dox-loaded 5D4-immunoliposomes specifically recognized prostate cancer cell lines of several different types expressing the mAb 5D4 antigen, PSMA, and significantly enhanced cytotoxicity toward these cells compared with the non-targeted Dox-liposomes in vitro while no increased toxicity was observed toward non-prostate (lung) cancer cell line.
负载阿霉素（Dox）的长循环脂质体用前列腺细胞特异性单克隆抗体5D4（mAb 5D4）进行了额外修饰。所得的负载阿霉素的5D4免疫脂质体特异性识别表达mAb 5D4抗原（前列腺特异性膜抗原，PSMA）的几种不同类型的前列腺癌细胞系，并且与非靶向阿霉素脂质体相比，在体外对这些细胞的细胞毒性显著增强，而对非前列腺（肺）癌细胞系未观察到毒性增加。
